Skip to content
10-Q

Quarterly Report

CORCEPT THERAPEUTICS INC CORT

0001628280-26-028902

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 107.35M sh
Shares Diluted Q1 2026 · Mar 31, 2026 104.44M sh
Shares Diluted Q1 2026 · Mar 31, 2025 119.82M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $0
Stock Repurchased Q1 2026 · Mar 31, 2025 $27.43M
Capex Q1 2026 · Mar 31, 2026 $201K
Capex Q1 2026 · Mar 31, 2025 $104K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$16.77M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 $4.77M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $108.74M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $120.5M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $89.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $637.99M
Stockholders Equity Q1 2026 · Dec 31, 2025 $647.81M
Stockholders Equity Q1 2026 · Mar 31, 2025 $683.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 $679.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $149.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $166.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $176.89M
Total Liabilities Q1 2026 · Dec 31, 2025 $188.85M
Current Assets Q1 2026 · Mar 31, 2026 $426.03M
Current Assets Q1 2026 · Dec 31, 2025 $485.46M
Total Assets Q1 2026 · Mar 31, 2026 $814.88M
Total Assets Q1 2026 · Dec 31, 2025 $836.65M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 $0.17
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 $0.19
Sga Expense Q1 2026 · Mar 31, 2026 $145.36M
Sga Expense Q1 2026 · Mar 31, 2025 $90.66M
Rd Expense Q1 2026 · Mar 31, 2026 $66.27M
Rd Expense Q1 2026 · Mar 31, 2025 $60.74M
Net Income Q1 2026 · Mar 31, 2026 −$31.76M
Net Income Q1 2026 · Mar 31, 2025 $20.55M
Operating Income Q1 2026 · Mar 31, 2026 −$49.6M
Operating Income Q1 2026 · Mar 31, 2025 $3.42M
Revenue Q1 2026 · Mar 31, 2026 $164.9M
Revenue Q1 2026 · Mar 31, 2025 $157.21M